Literature DB >> 9414264

Multiple myeloma: increasing evidence for a multistep transformation process.

M Hallek1, P L Bergsagel, K C Anderson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9414264      PMCID： PMC3901996     

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  305 in total

1.  The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling.

Authors:  E J Lowenstein; R J Daly; A G Batzer; W Li; B Margolis; R Lammers; A Ullrich; E Y Skolnik; D Bar-Sagi; J Schlessinger
Journal:  Cell       Date:  1992-08-07       Impact factor: 41.582

Review 2.  Hemopoietic cell growth factors and their receptors.

Authors:  N A Nicola
Journal:  Annu Rev Biochem       Date:  1989       Impact factor: 23.643

3.  Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines.

Authors:  M Hallek; C Neumann; M Schäffer; S Danhauser-Riedl; N von Bubnoff; G de Vos; B J Druker; K Yasukawa; J D Griffin; B Emmerich
Journal:  Exp Hematol       Date:  1997-12       Impact factor: 3.084

4.  Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells.

Authors:  Y Gazitt; C C Reading; R Hoffman; A Wickrema; D H Vesole; S Jagannath; J Condino; B Lee; B Barlogie; G Tricot
Journal:  Blood       Date:  1995-07-01       Impact factor: 22.113

5.  Phenotypic difference of normal plasma cells from mature myeloma cells.

Authors:  H Harada; M M Kawano; N Huang; Y Harada; K Iwato; O Tanabe; H Tanaka; A Sakai; H Asaoku; A Kuramoto
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

6.  Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells.

Authors:  M Pettersson; H Jernberg-Wiklund; L G Larsson; C Sundström; I Givol; Y Tsujimoto; K Nilsson
Journal:  Blood       Date:  1992-01-15       Impact factor: 22.113

7.  Multiple cytokines inhibit interleukin-6-dependent murine hybridoma/plasmacytoma proliferation.

Authors:  M Schwabe; G W Cox; M C Bosco; R Prohaska; H F Kung
Journal:  Cell Immunol       Date:  1996-02-25       Impact factor: 4.868

8.  Differences between Burkitt's lymphomas and mouse plasmacytomas in the immunoglobulin heavy chain/c-myc recombinations that occur in their chromosomal translocations.

Authors:  J R Müller; S Janz; M Potter
Journal:  Cancer Res       Date:  1995-11-01       Impact factor: 12.701

9.  Non-random chromosomal aberrations associated with multiple myeloma.

Authors:  J P Lewis; M R MacKenzie
Journal:  Hematol Oncol       Date:  1984 Oct-Dec       Impact factor: 5.271

10.  Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities.

Authors:  G Tricot; B Barlogie; S Jagannath; D Bracy; S Mattox; D H Vesole; S Naucke; J R Sawyer
Journal:  Blood       Date:  1995-12-01       Impact factor: 22.113
View more
  107 in total

Review 1.  Mechanisms of polyclonal hypogammaglobulinaemia in multiple myeloma (MM).

Authors:  M C Kyrtsonis; A Mouzaki; A Maniatis
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

2.  Deregulated cytokine network and defective Th1 immune response in multiple myeloma.

Authors:  M A Frassanito; A Cusmai; F Dammacco
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

3.  Establishment of an HS23 stromal cell-dependent myeloma cell line: fibronectin and IL-6 are critical.

Authors:  Akira Sakai; Miyo Oda; Mitsuhiro Itagaki; Noriaki Yoshida; Koji Arihiro; Akiro Kimura
Journal:  Int J Hematol       Date:  2010-10-06       Impact factor: 2.490

Review 4.  Multiple myeloma.

Authors:  N Raje; K C Anderson
Journal:  Curr Treat Options Oncol       Date:  2000-04

5.  The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance.

Authors:  Fiona M Ross; Laura Chiecchio; GianPaolo Dagrada; Rebecca K M Protheroe; David M Stockley; Christine J Harrison; Nicholas C P Cross; Alex J Szubert; Mark T Drayson; Gareth J Morgan
Journal:  Haematologica       Date:  2010-04-21       Impact factor: 9.941

6.  Adaptation to survival in germinal center is the initial step in onset of indolent stage of multiple myeloma.

Authors:  Ariosto S Silva; Robert A Gatenby
Journal:  Mol Pharm       Date:  2011-10-12       Impact factor: 4.939

7.  Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines.

Authors:  Xin Li; Angela Pennisi; Fenghuang Zhan; Jeffrey R Sawyer; John D Shaughnessy; Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2007-09       Impact factor: 6.998

8.  Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.

Authors:  Lucía López-Corral; Luis Antonio Corchete; María Eugenia Sarasquete; María Victoria Mateos; Ramón García-Sanz; Encarna Fermiñán; Juan-José Lahuerta; Joan Bladé; Albert Oriol; Ana Isabel Teruel; María Luz Martino; José Hernández; Jesús María Hernández-Rivas; Francisco Javier Burguillo; Jesús F San Miguel; Norma C Gutiérrez
Journal:  Haematologica       Date:  2014-05-09       Impact factor: 9.941

9.  Clinical stage-depending decrease of NK cell activity in multiple myeloma patients.

Authors:  Vladimir Jurisic; Tatjana Srdic; Gordana Konjevic; Olivera Markovic; Milica Colovic
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

10.  8-Chloroadenosine 3',5'-monophosphate induces cell cycle arrest and apoptosis in multiple myeloma cells through multiple mechanisms.

Authors:  Yi-Min Cheng; Qi Zhu; Yi-Yun Yao; Yong Tang; Ming-Ming Wang; Li-Fang Zou
Journal:  Oncol Lett       Date:  2012-09-11       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.